Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Plant Viral Movement Protein-expressing Yeast Transcriptome compared with Non-Functional Plant Viral Movement Protein-expressing Yeast Transcriptome

ABSTRACT: Virus life cycle heavily depends on their ability to command the host machinery in order to translate their genomes. By using a yeast-based approach we have found that over expression of the PNRSV MP caused a severe growth defect in yeast cells. cDNA microarrays analysis carried out to characterise at the molecular level the growth interference phenotype reported the induction of genes related to amino acid deprivation suggesting that expression of MP activates the GCN pathway in yeast cells.

ORGANISM(S): Saccharomyces cerevisiae

PROVIDER: GSE26120 | GEO | 2011/12/01

SECONDARY ACCESSION(S): PRJNA135361

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Plant Viral Movement Protein-expressing Yeast Transcriptome compared with Non-Functional Plant Viral Movement Protein-expressing Yeast Transcriptome

Project description:Virus life cycle heavily depends on their ability to command the host machinery in order to translate their genomes. By using a yeast-based approach we have found that over expression of the PNRSV MP caused a severe growth defect in yeast cells. cDNA microarrays analysis carried out to characterise at the molecular level the growth interference phenotype reported the induction of genes related to amino acid deprivation suggesting that expression of MP activates the GCN pathway in yeast cells. Yeast cell cultures were grown 24h in minimal medium with doxycycline (100 mg/ml). These cultures were then diluted to an OD600 nm of 0.1 into fresh minimal medium without doxycycline. At 6 h total RNA was extracted from yeast cells transformed with the pCM:MPpnrsv and MPpnrsvΔHR, a non-functional MPpnrsv mutant lacking its hydrophobic region.

2011-12-01 | E-GEOD-26120 | biostudies-arrayexpress

Plant Viral Movement Protein-expressing Yeast Transcriptome compared with wild-type Yeast Transcriptome

2011-12-01 | GSE26119 | GEO

Plant Viral Movement Protein-expressing Yeast Transcriptome compared with wild-type Yeast Transcriptome

Project description:Virus life cycle heavily depends on their ability to command the host machinery in order to translate their genomes. By using a yeast-based approach we have found that over expression of the PNRSV MP caused a severe growth defect in yeast cells. cDNA microarrays analysis carried out to characterise at the molecular level the growth interference phenotype reported the induction of genes related to amino acid deprivation suggesting that expression of MP activates the GCN pathway in yeast cells. Yeast cell cultures were grown 24h in minimal medium with doxycycline (100 mg/ml). These cultures were then diluted to an OD600 nm of 0.1 into fresh minimal medium without doxycycline. At 6 h total RNA was extracted from yeast cells transformed with the empty pCM262 vector (pCM construct) and pCM:MPpnrsv.

2011-12-01 | E-GEOD-26119 | biostudies-arrayexpress

Expression data from transgenic Nicotiana tabacum expressing a variant of coat protein and movement protein from Tobacco mosaic virus

Project description:Transgenic expression of viral proteins in natural host plants is a useful simplified system with the potential to understand the individual effect of each viral component. Transgenic expression of movement (MP) and a variant from coat protein (CPT42W) in tobacco, a TMV natural host, produces severe morphological changes, altered miRNAs accumulation and poor fertility. We used microarrays to characterize the gene expression changes caused by the co-expression of TMV capsid and movement proteins in Nicotiana tabacum comparing two isogenic lines MPxCPT42W and mpxcpT42W* (a line with both transgenes spontaneously silenced and with normal phenotype).

2012-12-01 | GSE37905 | GEO

Expression data from transgenic Nicotiana tabacum expressing a variant of coat protein and movement protein from Tobacco mosaic virus

2012-12-01 | E-GEOD-37905 | biostudies-arrayexpress

A plant virus movement protein regulates the Gcn2p kinase in budding yeast.

Project description: Not available

| S-EPMC3210792 | biostudies-literature

GAPDH--a recruits a plant virus movement protein to cortical virus replication complexes to facilitate viral cell-to-cell movement.

Project description: Not available

| S-EPMC4239097 | biostudies-literature

Identification of a Functional Plasmodesmal Localization Signal in a Plant Viral Cell-To-Cell-Movement Protein.

Project description: Not available

| S-EPMC4725018 | biostudies-literature

Transcriptional data from yeast expressing mammalian AKT1

Project description:We studied the transcriptional profile in yeast cells in response to heterologous expression of mammalian activated AKT1

2017-11-30 | GSE107482 | GEO

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

Project description:Objectives: * To find out the maximum tolerated dose of the GI-6207 vaccine (the highest dose that does not cause unacceptable side effects), and to evaluate any side effects. * To see if GI-6207 has any effect on patients tumors. * To learn how the vaccine causes immune responses against the cancer. Eligibility: * Patients 18 years of age and older who have been diagnosed with a cancer that has not responded to standard treatments. Patients must not be allergic to yeast or yeast products. Design: * Initial physical examination, blood and tissue sampling, computed tomography (CT) scan, and skin test to determine eligibility for the procedure. * Treatment with GI-6027 in seven 14-day cycles as follows: * Vaccine administered on days 1, 15, 29, 43, 57, 71, and 85. * Vaccine given at four sites around the body: right and left chest area below the armpit, and right and left upper thigh in the pelvic region. (These areas drain into parts of your body that contain large numbers of lymph nodes. The lymph nodes contain immune cells that may be activated by the vaccine to target cancer cells.) * Clinic visits for physical examinations to check vital signs, take additional blood and urine samples, and perform other tests needed for the study. * After day 85 (about 3 months), patients will continue to receive vaccine monthly (or every 28 days) as long as the vaccine is not producing harmful effects or side effects and the cancer is either stable or reducing. Patients who do well on the vaccine may continue to receive it for as long as it is available.

| 2073995 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data